Dyax Corp. and CSIRO Form Joint Antibody Discovery Collaboration in Oncology
Advertisement
Dyax Corp. and the Division of Molecular and Health Technologies of the Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australia's national scientific research agency, announced that they have entered into a collaboration for the discovery and development of therapeutic antibodies to treat cancer.
During the discovery phase of the collaboration, Dyax will utilize its proprietary antibody libraries to screen for clinical candidates, and CSIRO will provide reagents and in vitro assays, as well as certain in vivo and preclinical development work. Upon successful completion of the discovery work, CSIRO and Dyax will have the option to advance the antibody lead(s) into clinical development under the terms of a global co-development and commercialization agreement.
Other news from the department science
These products might interest you
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous